Median Technologies : Corporate Update and Webcast Replay – February 2023
February 03, 2023 at 06:10 am
Share
Corporate Update
2022 Achievements & 2023 Plans
February 2, 2023
Fredrik Brag
Chief Executive Officer and Founder
2023 & Beyond: The Big Take Off
Growing penetration of imaging AI in
patient care
RSNA 2022 key take away: Imaging AI is now a reality and will have a major impact on disease diagnostics
Breakthrough: 3 companies obtained a reimbursement of $650-$1,000 for imaging AI diagnostic solutions in 2022
Major study at RSNA showed 92% of LC patients alive after 15 years when diagnosed in Stage 1. Cancer is curable
People eligible for LCS in the US has doubled from 7.5m to 15m
European Union's initiative to accelerate implementation of LCS national programs, 22m people potentially eligible for LCS
The TAM is > $30bn in the US & EU and could double with Asia
iBiopsy® LCS SaMD has the highest performance
Growing penetration of imaging AI with
the pharma
Major interest for imaging AI by all life sciences stakeholders
Pharma operating a stage shift to treat early-stage disease to increase chance of success
Imaging AI will revolutionize drug development:
Cancer detection & characterization
Molecular status prediction
Response predictions / Companion diagnostics
Median Imaging lab can provide state of the art solutions
Median core iCRO business expected to grow significantly
Median intends to sign a strategic
Median intends to sign strategic
commercial partnership for the 2024
partnerships with big pharma
launch of LCS SaMD in the US
2 www.mediantechnologies.com | Company Webcast | February 2, 2023
2022 Achievements
3 www.mediantechnologies.com | Company Webcast | February 2, 2023
2022 Key Performance
As of December 31, 2022
2022 revenue at €23.8M
An increase of 16% compared to 2021 revenue (€20.5M).
Order backlog at €60.8M
Cash and cash equivalents at €21.5M
4 www.mediantechnologies.com | Company Webcast | February 2, 2023
25
20
15
10
5
0
Full Year Revenue (m€)
23.8
20.5
13.5
9
Full Year 2019
Full Year 2020
Full Year 2021
Full Year 2022
Nota: company revenue comes from the iCRO BU solely, as iBiopsy® doesn't generate revenue at this stage (R&D)
Release date: January 19, 2023
2022 Macro Geopolitical and Economic Impacts
Small and mid-caps hit by turmoil on
financial markets
Small & mid-caps hit by low liquidity
Median liquidity: Q4 2022 day-average:
€141k vs Q1 2022 day-average: €630k
Negative asset flows: technology, healthcare and biotechnology equity
The need for liquidity by certain funds have had a major impact on the share price
5 www.mediantechnologies.com | Company Webcast | February 2, 2023
China lockdown
The Chinese lockdown has had a major impact on our Chinese clients during the bigger part of 2022
The situation is expected to come back to normal quite quickly now that the country has opened up again
Inflation & general economic impact
Some of our mid size biotechs clients have had funding issues which have slowed down some expected trials. The larger biotechs are now getting funded
Perspectum raised $36m at $300m valuation
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Median Technologies SA published this content on 03 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 February 2023 11:07:09 UTC.
Median Technologies offers innovative imaging solutions and services to improve healthcare for all. The group uses the power of phenomic imaging to contribute to the emergence of new therapies and treatment strategies for patients. Its solutions, «iSee» for the image management in oncology trials and «iBiopsy», its phenomic imaging platform, combined with the expertise of its teams are an essential part to the discovery of new drugs and diagnostic tools to monitor diseases and evaluate the response of patients to their therapy. Median Technologies is helping biopharmaceutical companies and healthcare professionals quickly and accurately introduce new treatments to patients who need them, with a view to reducing overall costs of care.
Provision of services accounts for all net sales.
Net sales are distributed geographically as follows: France (4%), the United States and Canada (37%), China (19.2%), the United Kingdom (18.9%) and other (20.9%).